Allosteric Plus Catalytic BCR-ABL1 Inhibitors Promote Durable Responses [Kinase Inhibitors]
A selective allosteric ABL1 kinase inhibitor suppresses the growth of BCR–ABL1-driven CML.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: Kinase Inhibitors Source Type: research
More News: Cancer | Cancer & Oncology